Welcome to our dedicated page for Bath & Body Works SEC filings (Ticker: BBWI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bath & Body Works, Inc. filings document the public-company record for a Delaware specialty retailer whose common stock trades on the New York Stock Exchange under BBWI. Recent 8-K reports furnish quarterly and full-year operating results, earnings guidance, Regulation FD disclosures, debt redemption notices and executive officer changes.
Proxy materials describe board oversight, director elections, executive compensation, shareholder voting matters and governance practices tied to the company’s Consumer First Formula, brand, product, supply chain and store assets. The filings also identify registered common stock, senior notes disclosures and capital-structure matters for a personal care and home fragrance retail business.
STEINOUR STEPHEN D reported acquisition or exercise transactions in this Form 4 filing.
Bath & Body Works, Inc. director Stephen D. Steinour received an annual award of restricted stock units as an independent non-employee director. The award covers 7,970 shares of common stock at no cash cost, bringing his directly held shares to 56,145.
He also reports indirect ownership of common stock through two trusts, each holding 9,900 shares, and through his spouse, who holds 12,925 shares. These indirect positions reflect reported holdings rather than new market transactions.
Hondal Francis reported acquisition or exercise transactions in this Form 4 filing.
Bath & Body Works, Inc. director Francis Hondal reported an annual equity compensation grant. On June 11, 2026, Hondal received an award of 7,970 shares of common stock at $0.00 per share, described as an annual award of restricted stock units to independent non-employee directors.
After this grant, Hondal directly owned 13,611 shares of common stock. A separate entry shows indirect ownership of 15,913 shares held through The Francis A. Hondal Living Trust. No open-market purchases or sales were reported; the filing reflects routine director compensation and existing holdings.
Bath & Body Works, Inc. director Sarah E. Nash received an annual equity award in the form of restricted stock units. On June 11, 2026, she was granted 13,284 shares of common stock at no cash cost as director compensation. Following this grant, her direct holdings increased to 298,894.77 shares of common stock, which include 88.77 shares acquired through the company’s Dividend Reinvestment Plan.
Brady Lucy reported acquisition or exercise transactions in this Form 4 filing.
Bath & Body Works, Inc. director Lucy Brady reported an equity compensation award in the form of common stock. On June 11, 2026, she received a grant of 7,970 shares of common stock at no cash cost, described as an annual award of restricted stock units to independent non-employee directors. Following this grant, her direct holdings increased to 25,451.552 shares of Bath & Body Works common stock.
Bogliolo Alessandro reported acquisition or exercise transactions in this Form 4 filing.
Bath & Body Works director Alessandro Bogliolo received an equity grant of 7,970 shares of common stock. The award was made on June 11, 2026 as an annual grant of restricted stock units to an independent non-employee director. Following this grant, Bogliolo directly holds 24,490 shares of Bath & Body Works common stock.
Javitch Tom reported acquisition or exercise transactions in this Form 4 filing.
Bath & Body Works, Inc. reported that Interim CFO Tom Javitch received a grant of 10,309 shares of common stock on June 12, 2026 as a compensation award. The restricted stock units vest 100% on the one year anniversary of June 12, 2026. Following this grant, Javitch directly holds 59,003 common shares.
Bath & Body Works, Inc. held its Annual Meeting of Stockholders on June 11, 2026, where shareholders elected ten directors to one-year terms. Each nominee, including Alessandro Bogliolo and Sarah E. Nash, received substantially more votes for than against, with significant broker non-votes recorded.
Shareholders also ratified Ernst & Young LLP as independent registered public accounting firm for the 2026 fiscal year, with 178,656,095 shares voting for and 2,033,828 against. An advisory vote on executive compensation passed, receiving 159,868,611 votes in favor, representing 97.35% of votes cast on that proposal.
Bath & Body Works, Inc. executive Veronique Gabai-Pinsky, Chief Brand & Product Officer, filed an initial Form 3 reporting her holdings in the company. She reports direct ownership of 27,594 shares of common stock. A footnote describes an annual grant of restricted stock units vesting over three years, granted June 10, 2026.
Bath & Body Works, Inc. reported the initial share holdings of Chief Commercial Officer Maly Bernstein on a Form 3. Bernstein holds 67,356 shares of common stock directly. These holdings come from prior annual grants of restricted stock units that vest over a three-year schedule.
The footnote explains that the units vest 30% on the first anniversary of the grant date, 30% on the second, and 40% on the third. The total includes 38,402 outstanding shares from a grant dated December 10, 2025 and 28,954 outstanding shares from a grant dated March 12, 2026.
Bath & Body Works, Inc. executive David Andrew Meeting, who serves as SVP, Controller & Principal Accounting Officer, reported his beneficial ownership on a Form 3. He holds 19,794 shares of common stock directly, reflecting his existing equity position rather than a new transaction.
The total includes prior annual grants of restricted stock units that vest 30% on the first anniversary of the grant date, 30% on the second anniversary, and 40% on the third anniversary. These grants include 2,628 outstanding shares granted on March 13, 2024, 5,425 outstanding shares granted on March 13, 2025, and 11,741 outstanding shares granted on March 12, 2026.